• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

覆盖二元数据的层次狄利克雷混合模型,以增强肿瘤血液学中的基因组分层。

Covering Hierarchical Dirichlet Mixture Models on binary data to enhance genomic stratifications in onco-hematology.

机构信息

IRCCS Istituto delle Scienze Neurologiche di Bologna, Bologna, Italia.

Department of Hematology, Oncology and Cancer Immunology, Campus Virchow, Charité - Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Germany.

出版信息

PLoS Comput Biol. 2024 Feb 2;20(2):e1011299. doi: 10.1371/journal.pcbi.1011299. eCollection 2024 Feb.

DOI:10.1371/journal.pcbi.1011299
PMID:38306404
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC10880984/
Abstract

Onco-hematological studies are increasingly adopting statistical mixture models to support the advancement of the genomically-driven classification systems for blood cancer. Targeting enhanced patients stratification based on the sole role of molecular biology attracted much interest and contributes to bring personalized medicine closer to reality. In onco-hematology, Hierarchical Dirichlet Mixture Models (HDMM) have become one of the preferred method to cluster the genomics data, that include the presence or absence of gene mutations and cytogenetics anomalies, into components. This work unfolds the standard workflow used in onco-hematology to improve patient stratification and proposes alternative approaches to characterize the components and to assign patient to them, as they are crucial tasks usually supported by a priori clinical knowledge. We propose (a) to compute the parameters of the multinomial components of the HDMM or (b) to estimate the parameters of the HDMM components as if they were Multivariate Fisher's Non-Central Hypergeometric (MFNCH) distributions. Then, our approach to perform patients assignments to the HDMM components is designed to essentially determine for each patient its most likely component. We show on simulated data that the patients assignment using the MFNCH-based approach can be superior, if not comparable, to using the multinomial-based approach. Lastly, we illustrate on real Acute Myeloid Leukemia data how the utilization of MFNCH-based approach emerges as a good trade-off between the rigorous multinomial-based characterization of the HDMM components and the common refinement of them based on a priori clinical knowledge.

摘要

肿瘤血液病学研究越来越多地采用统计混合模型,以支持基于基因组的血液癌分类系统的发展。基于分子生物学的单一作用,针对增强患者分层的目标引起了很大的兴趣,并有助于使个性化医学更接近现实。在肿瘤血液病学中,层次狄利克雷混合模型 (HDMM) 已成为聚类基因组学数据的首选方法之一,这些数据包括基因突变和细胞遗传学异常的存在与否。这项工作展开了肿瘤血液病学中用于改善患者分层的标准工作流程,并提出了替代方法来描述组件并将患者分配给它们,因为它们是通常由先验临床知识支持的关键任务。我们提出 (a) 计算 HDMM 的多项成分的参数,或 (b) 估计 HDMM 成分的参数,就像它们是多元 Fisher 非中心超几何 (MFNCH) 分布一样。然后,我们设计的将患者分配给 HDMM 组件的方法旨在为每个患者确定其最可能的组件。我们在模拟数据上表明,使用基于 MFNCH 的方法进行患者分配可以优于,即使不可比,使用基于多项的方法。最后,我们在真实的急性髓细胞白血病数据上说明了如何利用基于 MFNCH 的方法来实现 HDMM 组件的严格基于多项的表征与基于先验临床知识的常见细化之间的良好折衷。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c25a/10880984/3b3266789f2b/pcbi.1011299.g005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c25a/10880984/7e2e066d7be1/pcbi.1011299.g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c25a/10880984/1c6c71111704/pcbi.1011299.g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c25a/10880984/b84567463b1d/pcbi.1011299.g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c25a/10880984/6461857d1008/pcbi.1011299.g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c25a/10880984/3b3266789f2b/pcbi.1011299.g005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c25a/10880984/7e2e066d7be1/pcbi.1011299.g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c25a/10880984/1c6c71111704/pcbi.1011299.g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c25a/10880984/b84567463b1d/pcbi.1011299.g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c25a/10880984/6461857d1008/pcbi.1011299.g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c25a/10880984/3b3266789f2b/pcbi.1011299.g005.jpg

相似文献

1
Covering Hierarchical Dirichlet Mixture Models on binary data to enhance genomic stratifications in onco-hematology.覆盖二元数据的层次狄利克雷混合模型,以增强肿瘤血液学中的基因组分层。
PLoS Comput Biol. 2024 Feb 2;20(2):e1011299. doi: 10.1371/journal.pcbi.1011299. eCollection 2024 Feb.
2
Exercise prescription and tailored physical activity intervention in onco-hematology inpatients, a personalized bedside approach to improve clinical best practice.在肿瘤血液病住院患者中制定运动处方和量身定制的体育活动干预措施,是一种个性化的床边方法,可改善临床最佳实践。
Hematol Oncol. 2019 Aug;37(3):277-284. doi: 10.1002/hon.2576. Epub 2019 Mar 18.
3
The challenge of targets and drug discovery using large-scale screening approaches in onco-hematology.在肿瘤血液病学中使用大规模筛选方法确定目标和药物发现所面临的挑战。
Therapie. 2022 Mar-Apr;77(2):151-155. doi: 10.1016/j.therap.2021.11.007. Epub 2021 Nov 25.
4
Cytogenetics in the management of acute myeloid leukemia: an update by the Groupe francophone de cytogénétique hématologique (GFCH).细胞遗传学在急性髓系白血病治疗中的应用:法国血液学细胞遗传学小组(GFCH)的最新进展
Ann Biol Clin (Paris). 2016 Oct 1;74(5):535-546. doi: 10.1684/abc.2016.1155.
5
[Flow cytogenetics. Principles, advantages and limitations. What trends for onco-hematology?].[流式细胞遗传学。原理、优势与局限。血液肿瘤学有哪些发展趋势?]
Pathol Biol (Paris). 1988 Jan;36(1):46-51.
6
A precision medicine classification for treatment of acute myeloid leukemia in older patients.精准医学分类治疗老年急性髓系白血病。
J Hematol Oncol. 2021 Jun 23;14(1):96. doi: 10.1186/s13045-021-01110-5.
7
Guidelines of the Italian Association of Pediatric Hematology and Oncology for the management of the central venous access devices in pediatric patients with onco-hematological disease.意大利儿科血液学和肿瘤学会关于儿童血液肿瘤疾病患者中心静脉通路装置管理的指南。
J Vasc Access. 2022 Jan;23(1):3-17. doi: 10.1177/1129729820969309. Epub 2020 Nov 10.
8
The challenge of risk stratification in acute myeloid leukemia with normal karyotype.正常核型急性髓系白血病的风险分层挑战。
Hematol Oncol Stem Cell Ther. 2008 Jul-Sep;1(3):141-58. doi: 10.1016/s1658-3876(08)50023-9.
9
[Strategy for diagnosing hematological malignancies--a proposal from hematologists to laboratory medicine].
Rinsho Byori. 2000 Aug;48(8):685-8.
10
Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.在流行地区,服用抗叶酸抗疟药物的人群中,叶酸补充剂与疟疾易感性和严重程度的关系。
Cochrane Database Syst Rev. 2022 Feb 1;2(2022):CD014217. doi: 10.1002/14651858.CD014217.

引用本文的文献

1
Classification and Prognostic Stratification Based on Genomic Features in Myelodysplastic and Myeloproliferative Neoplasm- and Their Overlapping Conditions.基于骨髓增生异常综合征、骨髓增殖性肿瘤及其重叠状态基因组特征的分类与预后分层
Cancers (Basel). 2024 Dec 9;16(23):4121. doi: 10.3390/cancers16234121.

本文引用的文献

1
Unified classification and risk-stratification in Acute Myeloid Leukemia.急性髓系白血病的统一分类和危险分层。
Nat Commun. 2022 Aug 8;13(1):4622. doi: 10.1038/s41467-022-32103-8.
2
The 5th edition of the World Health Organization Classification of Haematolymphoid Tumours: Lymphoid Neoplasms.《世界卫生组织造血与淋巴组织肿瘤分类》第五版:淋巴肿瘤。
Leukemia. 2022 Jul;36(7):1720-1748. doi: 10.1038/s41375-022-01620-2. Epub 2022 Jun 22.
3
Classification and Personalized Prognostic Assessment on the Basis of Clinical and Genomic Features in Myelodysplastic Syndromes.
基于骨髓增生异常综合征临床和基因组特征的分类及个性化预后评估
J Clin Oncol. 2021 Apr 10;39(11):1223-1233. doi: 10.1200/JCO.20.01659. Epub 2021 Feb 4.
4
Fast approximate inference for variable selection in Dirichlet process mixtures, with an application to pan-cancer proteomics.狄利克雷过程混合模型中用于变量选择的快速近似推断及其在泛癌蛋白质组学中的应用
Stat Appl Genet Mol Biol. 2019 Dec 12;18(6):/j/sagmb.2019.18.issue-6/sagmb-2018-0065/sagmb-2018-0065.xml. doi: 10.1515/sagmb-2018-0065.
5
Genome-scale MicroRNA target prediction through clustering with Dirichlet process mixture model.通过 Dirichlet 过程混合模型聚类进行全基因组 miRNA 靶标预测。
BMC Genomics. 2018 Sep 24;19(Suppl 7):658. doi: 10.1186/s12864-018-5029-7.
6
Genomic Classification and Prognosis in Acute Myeloid Leukemia.急性髓系白血病的基因组分类与预后
N Engl J Med. 2016 Jun 9;374(23):2209-2221. doi: 10.1056/NEJMoa1516192.
7
Heterogeneity of genomic evolution and mutational profiles in multiple myeloma.多发性骨髓瘤中基因组进化和突变谱的异质性
Nat Commun. 2014;5:2997. doi: 10.1038/ncomms3997.
8
Bayesian Nonparametric Inference - Why and How.贝叶斯非参数推断——为何及如何进行
Bayesian Anal. 2013;8(2). doi: 10.1214/13-BA811.
9
Patient-specific data fusion defines prognostic cancer subtypes.个体化患者数据融合定义了预后癌症亚型。
PLoS Comput Biol. 2011 Oct;7(10):e1002227. doi: 10.1371/journal.pcbi.1002227. Epub 2011 Oct 20.